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ABSTRACT
A controlled, parallel, randomized and comparative trial was carried out to evaluate the anti-
inﬂammatory efﬁcacy of IMMUNEPOTENT CRP versus ibuprofen in patients after third-molar
surgery over seven days. The anti-inﬂammatory efﬁcacy of IMMUNEPOTENT CRP was evaluated
using the method of Amin and Laskin, and the analysis of cytokine production (IL-2, IL-4, IL-6, IL-10,
TNF-a, INF-g) in saliva was done by ﬂow cytometry. The swelling process after surgery was
signiﬁcant (p < 0.05) and the treatments with IMMUNEPOTENT CRP or ibuprofen controlled this
process properly; no difference between the groups was found (p < 0.05). Both treatments were
shown to modulate the cytokine production. These results demonstrate the anti-inﬂammatory
activity of the natural compound IMMUNEPOTENT CRP and suggest it could be used in clinical
dental practice.
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Introduction
Third-molar surgical extraction is the most common trau-
matic procedure in the ﬁeld of oral and maxillofacial sur-
gery. Since the area of the third-molar is highly
vascularized and is rich in loose connective tissue, this
surgical procedure is typically followed by liberation of
exudate and subsequent swelling, trismus, pain, etc., for
which appropriate treatment is needed [1]. The manage-
ment of these postoperative symptoms is frequently
based on pharmacological manipulation of local and sys-
temic mediators of pain and inﬂammation [2]. For con-
trol of postoperative pain and trismus resulting from
lower third-molar surgery, some non-steroidal anti-
inﬂammatory drugs (NSAIDs) are generally used [3,4].
Among NSAIDs used in dentistry, ibuprofen, a non-selec-
tive COX inhibitor with a highly effective analgesic and
anti-inﬂammatory action, has been largely studied [5–7].
However, many NSAIDs have side effects, such as gastro-
intestinal irritation, ulcers and bleeding, and can also
aggravate some inﬂammatory responses [8,9]. Due to
the undesirable side effects of steroidal and NSAID medi-
cations, there is growing interest in natural compounds,
which can reduce pain and inﬂammation by inhibiting
the inﬂammatory pathways in a manner similar to
NSAIDs [10]. Pro-inﬂammatory cytokines are a measur-
able marker of post-traumatic pain, fever and inﬂamma-
tion and have been isolated in many body systems,
including saliva in the oral cavity. Cytokines, such as
tumour necrosis factor alpha (TNF-a), have a wide range
of pro-inﬂammatory and immunomodulatory effects
including remodelling of ﬁbroblasts and osteoblasts, but
TNF-a can lead to a variety of pathological conditions
[8]. Interleukin-6 (IL-6) has been traditionally considered
to be a pro-inﬂammatory cytokine and the production of
IL-6 is higher after surgical extraction of lower third
molars probably due to trauma caused by extraction
[11]. Decreasing the local and systemic cytokines levels
with the use of drugs is a well-known method for reduc-
ing clinical inﬂammation [12]. The natural compound
IMMUNEPOTENT CRP is a dialysate of a heterogeneous
mixture of low-molecular-weight substances released
from lymphoid tissue obtained from homogenized
bovine spleen. It has been patented in Mexico (NL/a/
2004/000058, IMPI) [13] and registered under the trade
mark IMMUNEPOTENT CRP. IMMUNEPOTENT CRP is a
complementary alternative medicine used for improve-
ment of the immune response in a broad spectrum of
diseases such as cancer [14,15], endotoxic shock and
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infections [16]. Our research group has demonstrated
that IMMUNEPOTENT CRP increases the total antioxidant
activity, catalase, glutathione peroxidase and superoxide
dismutase activities and decreases the NO, TNF-a pro-
duction, cyclo-oxygenase-2 (COX-2) and prostaglandin
E2 (PGD2) activities, IkB phosphorylation, NFkB p50 and
p65 subunit DNA-binding activity in lipopolysaccharide
(LPS)-induced human macrophages [17]. The results
obtained in vivo have demonstrated that IMMUNEPO-
TENT CRP improved the survival in LPS-induced murine
endotoxic shock [16] and human neonatal sepsis [18]. In
the present study, a controlled, parallel, randomized and
comparative trial was carried out to evaluate the anti-
inﬂammatory activity of IMMUNEPOTENT CRP versus ibu-
profen in patients after third-molar surgery over a seven-
day research period.
Subjects and methods
IMMUNEPOTENT CRP
The IMMUNEPOTENT CRP used in this study was pro-
duced by the Laboratory of Immunology and Virology,
Department of Microbiology and Immunology, Faculty of
Biological Sciences, Autonomous University of Nuevo
Leon (San Nicolas de los Garza, Nuevo Leon, Mexico). It is
a mixture of low-molecular weight molecules (cut-off of
10–12 kDa) obtained by dialysis of disintegrated bovine
spleens against water. The IMMUNEPOTENT CRP is then
lyophilized and analysed to be free of pyrogens by the
Limulus amoebocyte lysate assay (Endotoxin detection
kit; MP Biomedicals Inc., Aurora, OH, USA) and determined
to be free of bacterial contamination by culturing IMMU-
NEPOTENT CRP in different culture media and in vivo
mouse inoculation. The IMMUNEPOTENT CRP obtained
from 15£ 108 leukocytes is deﬁned as 1 unit (1 U).
Patients
The study was approved by the Human Research Ethics
Committee of the Faculty of Odontology of the Autono-
mous University of Nuevo Leon. Informed written con-
sent was obtained from all patients, according to the
ethical committee and the Helsinki Declaration of 1975,
as revised in 2008. This prospective study included 20
ASA PS1 patients (American Society of Anesthesiology
classiﬁcation, normal healthy patients) [19] with mandib-
ular third-molar impactions class IIB according to the
Pell–Gregory scale [20].
The surgery had a limited time of 45 minutes. The
patient population was randomly and consecutively
selected from an outpatient oral and maxillofacial sur-
gery clinic. Care was taken to maintain that the trial was
in compliance with the current CONSORT (Consolidated
Standards of Reporting Trials) statement guidelines.
Other criteria for inclusion into the study included: age
between 18 and 40 years; no systemic disease (ASA I sta-
tus); patients were not taking any medication before sur-
gery; no allergies to any of the study compounds
administered and absence of local or systemic infection.
All patients underwent an initial preoperative screening
consultation with a single oral and maxillofacial surgery
faculty-in-residence and a faculty member. All of the
enrolled patients completed the study without any post-
operative complications. All extractions were performed
by one surgeon and required full-thickness mucoperios-
teal ﬂaps and bone removal (performed under irrigation)
using an air-driven rotary instrument. A uniform local
anaesthetic technique was used which included unilateral
inferior alveolar, lingual and long buccal nerve blocks
using 2% lidocaine with 1:100,000 epinephrine. The
patients were randomly divided into two groups using a
random number generated by a computer (10 patients
per group). An independent pharmacist dispensed either
ibuprofen or IMMUNEPOTENT CRP medications according
to computer-generated randomization. The two groups
were as follows: group 1 received immediate preoperative
ibuprofen 600 mg, which was continued every 8 h post-
operatively for 3 days, and group 2 received immediate
preoperative 5 U of IMMUNEPOTENT CRP, which was con-
tinued every 12 h postoperatively for 3 days. All groups
received ketorolac tromethamine 10 mg every 6 h for
3 days and amoxicillin 750 mg every 8 h for 7 days for
postoperative pain and antibiotic management. All com-
pounds were administered by oral route.
Measurement of swelling
The measurement of facial swelling was done by the
method described by Amin and Laskin [21]. The distance
between the lower attachment of the ear lobe to the cor-
ner of the mouth, the distance between the lower
attachment of the ear lobe to the mandibular symphysis
and the vertical distance between the angle of the man-
dible to the outer canthus of the eye were measured by
means of a silk suture. This measurement was done prior
to surgery along the natural convexity of the patients’
face and the measurements were taken immediately
before surgery and on the third and seventh postopera-
tive days. The observation was recorded for statistical
analysis and the results were tabulated.
Determination of cytokines
Cytokines were determined as biomarkers reﬂecting the
patients’ health status and/or intervention outcomes.
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Saliva samples were used as a less invasive and more
convenient procedure than blood samples. Brieﬂy, saliva
samples (1 mL) were collected from patients before sur-
gery, and on the third and seventh postoperative days.
The detritus was eliminated from the saliva by centrifu-
gation (400£g) and the samples were stored at ¡20 C
until cytokine determination. The saliva levels of Th1 and
Th2 human cytokines were determined by ﬂow cytome-
try (Accuri C6, BD Bioscienses, CA, USA) using a CBA Th1/
Th2 Cytokine Kit II BDTM (BD Biosciences, Bedford, MA,
USA), following the manufacturer’s instructions. Cyto-
kines were analyzed by using FCAP array v1.0 software
(Soft Flow Inc., Minneapolis, MN, USA). Protein values
were converted to NIBSC/WHO protein standards
(National Institute for Biological Standards and Control/
World Health Organization) for further comparisons.
Statistical analysis
All statistical analyses were done using Statistical Pack-
age for Social Science (SPSS 18.0). The differences
between the two groups regarding the median facial
swelling measurements and median saliva cytokines
levels were compared using Mann–Whitney U-test and a
p-value of less than 0.05 was considered signiﬁcant.
Results and discussion
The third-molar extraction pain model is a recognized
model for evaluation of the effect of anti-inﬂammatory
drugs [20]. The technique used in this study to measure
the inﬂammatory processes was the method of Amin
and Laskin because it is economical, simple and repro-
ducible and has been used by many researchers [22,23].
There are also several linear methods used, such as facial
arcs and callipers [24,25], as well as two-dimensional
methods such as photographs, modiﬁed face arcs and
scans; the use of subjective methods, such as facial arcs
and callipers, is common [26]. Furthermore, each tech-
nique has advantages and disadvantages depending on
the experience of the personnel and the method used.
For example, in a study by Villafuerte-Nu~nez [27], the
proposed technique consists in measuring inﬂammation
through a three-dimensional reconstruction of the area
affected by facial edema using the structured light tech-
nique by using image-processing and the combination
of different devices. The authors pointed out that the
main advantages are the scanning speed and the accu-
racy but concluded that the system allows obtaining
accurate results while the illumination of the environ-
ment is controlled [27]. Actually, the removal of the third
molar is a very common procedure and the secondary
effects are swelling, pain and trismus. In a study to
evaluate two anti-inﬂammatory drugs (ibuprofen and/or
dexamethasone) in third-molar surgery, no statistically
signiﬁcant advantage was found between treatments,
suggesting that ibuprofen could be used as a single anti-
inﬂammatory drug in the management of this procedure
[12,28]. In recent studies, submucosal dexamethasone
has been used as treatment to control postoperative dis-
comfort, showing a signiﬁcant reduction of pain, swell-
ing and truisms compared with NSAIDs [29]. The
difference in these studies could be the administration
route.
Our results showed that the group of patients treated
with ibuprofen showed a higher increase (3.26%) in the
swelling percentage from day 0 to day 3 (p< 0.01) and a
signiﬁcant decrease in the swelling percentage to 1.0%
on day 7 (p< 0.05) (Table 1). A similar trend was
observed in the group of patients treated with IMMUNE-
POTENT CRP: they showed a 2.61% increase in the swell-
ing percentage from day 0 to day 3 (p < 0.05) and a
signiﬁcant decrease of the swelling percentage to 0.63%
on day 7 (p< 0.05) (Table 1). However, no signiﬁcant dif-
ferences (p> 0.05) were found between the swelling
percentages after treatment in the two study groups
(Table 2). These ﬁndings could be associated with the
control of pro-inﬂammatory cytokines. That is why, as
next step, we evaluated the levels of some saliva cyto-
kines on day 0, 3 and 7 in the groups treated with ibu-
profen or IMMUNEPOTENT CRP. The obtained results,
however, showed non-signiﬁcant differences in the stud-
ied cytokine levels between the two types of treatment
and the three days of sampling (p > 0.05), although high
IL-6 production was observed in both treatment groups
(Table 3).
Table 1. Intragroup comparisons of the percentage of swelling.
Group Day 0 Day 3 Day 7
Ibuprofen 0%c 3.26% 1.0%b
IMMUNEPOTENT CRP 0%d 2.61%e 0.63%f
Note: The percentage of swelling was determined by the method of Amin
and Laskin [21].
a p< 0.05 between day 0 and 3 in the ibuprofen group.
bp< 0.001 between day 3 and 7 in the ibuprofen group.
c p< 0.001 between day 0 and 7 in the ibuprofen group.
dp< 0.05 between day 0 and 3 in the IMMUNEPOTENT CRP group.
e p< 0.05 between day 3 and 7 in the IMMUNEPOTENT CRP group.
f p< 0.05 between day 0 and 7 in the IMMUNEPOTENT CRP group.
Table 2. Comparison of the percentage of swelling between
groups.
Ibuprofen IMMUNEPOTENT CRP p Valuea
Day 0–0 0% 0% –
Day 3–3 3.26% 2.61% 0.988
Day 7–7 1% 0.63% 0.447
Note: The percentage of swelling was calculated by the method of Amin
and Laskin [21] at different times pre- and post-operatively.
a p< 0.05 was considered signiﬁcant.
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For the reduction of postoperative inﬂammation, it is
necessary to control the synthesis of cytokines, because
they participate in the process of tissue repair, chemo-
taxis and control of inﬂammation [30]. As cytokines have
a very important role during inﬂammation, they can be
used as a target to control chronic inﬂammation [30].
The presence of INF-g , IL-10, IL-4 and IL-6 could play a
role in the process of tissue repair, chemotaxis and con-
trol of inﬂammation because the healing process was
successful in the patients who participated in our study.
Similar results have been reported in the control of cyto-
kines and pro-inﬂammatory metabolites in other studies
of the inﬂammatory model with ibuprofen [5,6]. In the
present study, the inﬂammatory response caused by
cytokines was evaluated in the saliva, which is a repre-
sentative ﬂuid of the local microenvironment next to the
area of the surgery. The ﬂow cytometry technique was
used for determination of the saliva cytokine levels
because this technique has been found to be more sen-
sitive in the detection of cytokines [31]. Well-known
adverse effects of ibuprofen are: nausea, gastrointestinal
bleeding, elevated liver enzymes, diarrhoea, constipa-
tion, epistaxis, headache, dizziness, rash, salt and ﬂuid
retention, and hypertension. Similar to other NSAIDs,
ibuprofen may show photo-sensitising properties and
also has been implicated in increasing the risk of myo-
cardial infarction particularly in those who use high
doses chronically [32]. During our study, the patients of
both treatments did not present discomfort about pain
related to third-molar surgery. This could probably be
due to the administration of ketorolac, as Christensen
et al. [33] reported that ketorolac has an analgesic effect
in the third-molar surgery, and not anti-inﬂammatory
activity.
Overall, our study showed some promising results
about the potential use of IMMUNEPOTENT CRP in third-
molar surgery. There are, however, some limitations that
need to be mentioned: it was a preliminary trial, with
just 10 patients per group. Despite this limitation,
our study provides interesting results in the dental sur-
gery ﬁeld and we are now considering a larger-scale clin-
ical trial.
Conclusions
Our results demonstrated that ibuprofen or IMMUNEPO-
TENT CRP treatments were efﬁcient in the control of
inﬂammation through cytokines modulation without
having side effects in third-molar surgery, suggesting
they could be considered appropriate for use in dental
clinical practice. Further, larger-scale trials, however, are
necessary to corroborate the anti-inﬂammatory proper-
ties and to investigate the wound healing effects.
Disclosure statement
No potential conﬂict of interest was reported by the authors.
Funding
This work was supported by the Laboratory of Immunology
and Virology, Faculty of Biological Sciences, Autonomous
University of Nuevo Leon (San Nicolas de los Garza, NL,
Mexico), in collaboration with CONACYT, ‘Red Tematica de
Inmunologıa en Cancer y Enfermedades Infecciosas’ [grant
number 253053].
ORCID
Cristina Rodrıguez-Padilla http://orcid.org/0000-0001-5469-
8449
References
[1] Al-Saffar MT. Efﬁcacy of paracetamol versus celebrex on
the control of post-operative complications of lower third
molars. Dent J. 2011;11(1):24–31.
[2] Laureano Filho JR, Maurette PE, Allais M, et al. Clinical
comparative study of the effectiveness of two dosages of
Dexamethasone to control postoperative swelling, trismus
and pain after the surgical extraction of mandibular
impacted third molars. Med Oral Patol Oral Cir Bucal.
2008;13(2):E129–132.
[3] Barden J, Edwards JE, McQuay HJ, et al. Relative efﬁcacy of
oral analgesics after third molar extraction. Br Dent J.
2004;197(7):407–411.
[4] Urquhart E. Analgesic agents and strategies in the dental
pain model. J Dent. 1994;22(6):336–341.
Table 3. Saliva cytokines production in patients given ibuprofen or IMMUNEPOTENT CRP.
Ibuprofen (days) IMMUNEPOTENT CRP (days)
Cytokines (pg/mL) 0 3 7 0 3 7
INF 0.92 § 0.24 4.40 § 1.94 1.46 § 0.46 1.4 § 0.52 2.64 § 0.94 3.56 § 1.54
TNF 3.95 § 2.22 8.33 § 4.77 9.64 § 4.05 3.91 § 1.40 5.75 § 2.54 11.78 § 6.49
IL-2 0.41 § 0.26 0.64 § 0.38 0.383 § 0.17 0.46 § 0.19 0.36 § 0.13 0.60 § 0.36
IL-4 0.14 § 0.11 0.20 § 0.15 0.09 § 0.03 0.12 § 0.08 0.09 § 0.06 0.18 § 0.11
IL-6 24.02 § 17.24 438.47 § 164.32 199.30 § 39.18 46.81 § 18.95 355.22 § 161.73 468.22 §160.63
IL-10 0.14 § 0.11 0.99 § 0.43 0.63 § 0.36 0.11 § 0.09 0.28 § 0.16 0.81 § 0.43
Note: Saliva cytokines production was determined by ﬂow cytometry.
There were no statistically signiﬁcant differences between groups (p > 0.05).
BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT 185
[5] Giles AD, Hill CM, Shepherd JP, et al. A single dose assess-
ment of an ibuprofen/codeine combination in postoperative
dental pain. Int J Oral Maxillofac Surg. 1986;15(6):727–732.
[6] L€okken P, Olsen I, Bruaset I, et al. Bilateral surgical removal
of impacted lower third molar teeth as a model for drug
evaluation: a test with ibuprofen. Eur J Clin Pharmacol.
1975;8:209–216.
[7] Malmstrom K, Sapre A, Couglin H, et al. Etoricoxib in acute
pain associated with dental surgery: a randomized, dou-
ble-blind, placebo- and active comparator-controlled
dose-ranging study. Clin Ther. 2004;26(5):667–679.
[8] Endres S, Whitaker RE, Ghorbani R, et al. Oral aspirin and
ibuprofen increase cytokine-induced synthesis of IL-1
beta and of tumour necrosis factor-alpha ex vivo. Immu-
nology. 1996;87(2):264–270.
[9] Tanaka K-I, Suemasu S, Ishihara T, et al. Inhibition of both
COX-1 and COX-2 and resulting decrease in the level of
prostaglandins E2 is responsible for non-steroidal anti-
inﬂammatory drug (NSAID)-dependent exacerbation of
colitis. Eur J Pharmacol. 2009;603(1–3):120–132.
[10] Maroon JC, Bost JW, Maroon A. Natural anti-inﬂammatory
agents for pain relief. Surg Neurol Int [Internet]. 2010
[cited 2016 Sep 20];1:80. Available from: https://www.
ncbi.nlm.nih.gov/pmc/articles/PMC3011108/
[11] Lopez Carriches C, Martınez Gonzalez JM, Donado
Rodrıguez M. Variations of interleukin-6 after surgical
removal of lower third molars. Med Oral Patol Oral Cir
Bucal. 2006;11(6):E520–526.
[12] Mehra P, Reebye U, Nadershah M, et al. Efﬁcacy of anti-
inﬂammatory drugs in third molar surgery: a randomized
clinical trial. Int J Oral Maxillofac Surg. 2013;42(7):835–842.
[13] IMPI: Portal ViDoc plus v2.3.1 - Visor de Propiedad Indus-
trial [Internet]. [citated 2016 Oct 24];[about 1 screen].
Available from: http://vidoc.impi.gob.mx/ViDoc/visor.do?
Param=VIDOC$PA$E$NL/a/2004/000058
[14] Franco-Molina MA, Mendoza-Gamboa E, Zapata-Bena-
vides P, et al. Antiangiogenic and antitumor effects of
IMMUNEPOTENT CRP in murine melanoma. Immunophar-
macol Immunotoxicol. 2010;32(4):637–646.
[15] Mendoza-Gamboa E, Franco-Molina MA, Zapata-Bena-
vides P, et al. Bovine dialyzable leukocyte extract modu-
lates AP-1 DNA-binding activity and nuclear transcription
factor expression in MCF-7 breast cancer cells. Cytother-
apy. 2008;10(2):212–219.
[16] Franco-Molina MA, Mendoza-Gamboa E, Castillo-Leon L,
et al. Bovine dialyzable leukocyte extract protects against
LPS-induced, murine endotoxic shock. Int Immunophar-
macol. 2004;4(13):1577–1586.
[17] Miranda-Hernandez DF. Anti-inﬂammatory and antioxi-
dant effects of IMMUNEPOTENT CRP in lipopolysaccharide
(LPS)-stimulated human macrophages. Afr J Microbiol
Res. 2011;5(22):3726–3736.
[18] Rodriguez-Balderrama I, Perez-Martinez P, Jimenez-
Gonzales G, et al. Use of transfer factor in new born childs
with septic shock. Rev Mex Pediatrıa. 1999;66(6):240–245.
Spanish.
[19] ASA physical status classiﬁcation system [Internet].
Schaumburg (IL): American Society of Anesthesiologists;
c1995–2016 [cited 2016 Sep 20]. Available from: https://
www.asahq.org/resources/clinical-information/asa-physi
cal-status-classiﬁcation-system
[20] Garcıa AG, Sampedro FG, Rey JG, et al. Pell–Gregory classi-
ﬁcation is unreliable as a predictor of difﬁculty in extract-
ing impacted lower third molars. Br J Oral Maxillofac Surg.
2000;38(6):585–587.
[21] Amin MM, Laskin DM. Prophylactic use of indomethacin
for prevention of post-surgical removal of impacted lower
third molar. Al-Raﬁdain Dent. 1983;6:114–121.
[22] Mehlisch DR. The efﬁcacy of combination analgesic ther-
apy in relieving dental pain. J Am Dent Assoc. 2002;133
(7):861–871.
[23] Ata-Ali J, Ata-Ali F, Pe~narrocha-Oltra D, et al. Corticoste-
roids use in controlling pain, swelling and trismus after
lower third molar surgery. J Clin Exp Dent. 2011;3(5):469–
475.
[24] Bacci C, Cassetta G, Emanuele B, et al. Randomized split-
mouth study on postoperative effects of palmitoylethano-
lamide for impacted lower third molar surgery. ISRN Surg
[Internet]. 2011 [cited 2016 Sep 20];2011:917350. Avail-
able from: https://www.hindawi.com/journals/isrn/2011/
917350/.
[25] Bjørnsson GA, Haanaes HR, Skoglund LA. A randomized,
double-blind crossover trial of paracetamol 1000 mg four
times daily vs ibuprofen 600 mg: effect on swelling and
other postoperative events after third molar surgery. Br J
Clin Pharmacol. 2003;55(4):405–412.
[26] Vegas-Bustamante E, Mico-Llorens J, Gargallo-Albiol J,
et al. Efﬁcacy of methylprednisolone injected into the
masseter muscle following the surgical extraction of
impacted lower third molars. Int J Oral Maxillofac Surg.
2008;37(3):260–263.
[27] Villafuerte-Nu~nez, E, Tellez-Anguiano A, Hernande-Dıaz O,
et al. Facial edema evaluation using digital image process-
ing. Discrete Dyn Nat Soc Discrete Dyn Nat Soc [Internet].
2013 [cited 2016 Sep 20];2013:927843. Available from:
https://www.hindawi.com/journals/ddns/2013/927843/
[28] Landucci A, Wosny AC, Uetanabaro LC, et al. Efﬁcacy of
a single dose of a low-level of laser therapy in reduc-
ing pain, swelling and trismus following third molar
extraction surgery. Int J Oral Maxillofac Surg. 2016;45
(3):392–398.
[29] Riaz W, Madiha R, Anjum S, et al. Evaluation of postopera-
tive discomfort following third molar surgery using sub-
mucosal dexamethasone – a randomized observer blind
prospective study. Oral Surg Oral Med Oral Pathol Oral
Radiol. 2013;116(1):16–22.
[30] Zhang J-M, An J. Cytokines, inﬂammation and pain. Int
Anesthesiol Clin. 2007;45(2):27–37.
[31] Ooi KG-J, Galatowicz G, Towler HMA, et al. Multiplex cyto-
kine detection versus ELISA for aqueous humor: IL-5, IL-
10, and IFNgamma proﬁles in uveitis. Invest Ophthalmol
Vis Sci. 2006;47(1):272–277.
[32] Geisslinger G, Dietzel K, Bezler H, et al. Therapeutically
relevant differences in the pharmacokinetical and
pharmaceutical behavior of ibuprofen lysinate as
compared to ibuprofen acid. Int J Clin Pharmacol. 1989;
27(7):324–328.
[33] Christensen K, Daniels S, Bandy D, et al. A double-blind
placebo-controlled comparison of a novel formulation of
intravenous diclofenac and ketorolac for postoperative
third molar extraction pain. Anesth Prog. 2011;58(2):73–
81.
186 M. A. FRANCO-MOLINA ET AL.
